Single User License
INR 128840
Site License
INR 257680
Corporate User License
INR 386520

Service Tax Additional

select a format
Price

Single User License
USD 2000
Site License
USD 4000
Corporate User License
USD 6000

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ... "Mohit Mittal, Consultant, KPMG Advisory Services"

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies.... "Mustafa Masood, Financial Analyst , Coldwell Banker Riyadh"

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"


Germ Cell Tumors-Pipeline Review, H2 2015

Germ Cell Tumors-Pipeline Review, H2 2015


  • Products Id :- GMDHC7014IDB
  • |
  • Pages: 88
  • |
  • August 2015
  • |
  • |
  Request for Sample Report

Executive Summary

Germ Cell Tumors-Pipeline Review, H2 2015

Summary

Global Markets Direct's, 'Germ Cell Tumors-Pipeline Review, H2 2015', provides an overview of the Germ Cell Tumors's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Germ Cell Tumors, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Germ Cell Tumors and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

The report provides a snapshot of the global therapeutic landscape of Germ Cell Tumors

The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in the therapeutics development for Germ Cell Tumors and enlists all their major and minor projects

The report summarizes all the dormant and discontinued pipeline projects

A review of the Germ Cell Tumors products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

A detailed assessment of monotherapy and combination therapy pipeline projects

Coverage of the Germ Cell Tumors pipeline on the basis of target, MoA, route of administration and molecule type

Latest news and deals relating related to pipeline products

Reasons To Buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Develop strategic initiatives by understanding the focus areas of leading companies

Identify and understand important and diverse types of therapeutics under development for Germ Cell Tumors

Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

Devise corrective measures for pipeline projects by understanding Germ Cell Tumors pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications
ankur [@] kenresearch.com
+91-9015378249
www.kenresearch.com

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 5

Introduction 6

Global Markets Direct Report Coverage 6

Germ Cell Tumors Overview 7

Therapeutics Development 8

Pipeline Products for Germ Cell Tumors-Overview 8

Pipeline Products for Germ Cell Tumors-Comparative Analysis 9

Germ Cell Tumors-Therapeutics under Development by Companies 10

Germ Cell Tumors-Therapeutics under Investigation by Universities/Institutes 11

Germ Cell Tumors-Pipeline Products Glance 12

Clinical Stage Products 12

Early Stage Products 13

Germ Cell Tumors-Products under Development by Companies 14

Germ Cell Tumors-Products under Investigation by Universities/Institutes 15

Germ Cell Tumors-Companies Involved in Therapeutics Development 16

AB Science SA 16

ArQule, Inc. 17

Astex Pharmaceuticals, Inc. 18

GlaxoSmithKline Plc 19

MediGene AG 20

Merck & Co., Inc. 21

Novartis AG 22

Philogen S.p.A. 23

Sanofi 24

Germ Cell Tumors-Therapeutics Assessment 25

Assessment by Monotherapy Products 25

Assessment by Combination Products 26

Assessment by Target 27

Assessment by Mechanism of Action 29

Assessment by Route of Administration 31

Assessment by Molecule Type 33

Drug Profiles 35

cabazitaxel-Drug Profile 35

Product Description 35

Mechanism of Action 35

R&D Progress 35

Cell Therapy 1 for Oncology-Drug Profile 37

Product Description 37

Mechanism of Action 37

R&D Progress 37

(dabrafenib mesylate + trametinib dimethyl sulfoxide)-Drug Profile 38

Product Description 38

Mechanism of Action 38

R&D Progress 38

G-207-Drug Profile 40

Product Description 40

Mechanism of Action 40

R&D Progress 40

guadecitabine-Drug Profile 42

Product Description 42

Mechanism of Action 42

R&D Progress 42

pembrolizumab-Drug Profile 46

Product Description 46

Mechanism of Action 46

R&D Progress 46

ribociclib-Drug Profile 55

Product Description 55

Mechanism of Action 55

R&D Progress 55

Small Molecule to Antagonize KIT816 for Aggressive Mastocytosis, Seminoma and AML-Drug Profile 58

Product Description 58

Mechanism of Action 58

R&D Progress 58

Small Molecules to Inhibit Tubulin for Oncology-Drug Profile 59

Product Description 59

Mechanism of Action 59

R&D Progress 59

Tetravil-Drug Profile 60

Product Description 60

Mechanism of Action 60

R&D Progress 60

tivantinib-Drug Profile 62

Product Description 62

Mechanism of Action 62

R&D Progress 62

Germ Cell Tumors-Recent Pipeline Updates 65

Germ Cell Tumors-Dormant Projects 86

Appendix 87

Methodology 87

Coverage 87

Secondary Research 87

Primary Research 87

Expert Panel Validation 87

Contact Us 87

Disclaimer 88

List of Tables

Number of Products under Development for Germ Cell Tumors, H2 2015 8

Number of Products under Development for Germ Cell Tumors-Comparative Analysis, H2 2015 9

Number of Products under Development by Companies, H2 2015 10

Number of Products under Investigation by Universities/Institutes, H2 2015 11

Comparative Analysis by Clinical Stage Development, H2 2015 12

Comparative Analysis by Early Stage Development, H2 2015 13

Products under Development by Companies, H2 2015 14

Products under Investigation by Universities/Institutes, H2 2015 15

Germ Cell Tumors-Pipeline by AB Science SA, H2 2015 16

Germ Cell Tumors-Pipeline by ArQule, Inc., H2 2015 17

Germ Cell Tumors-Pipeline by Astex Pharmaceuticals, Inc., H2 2015 18

Germ Cell Tumors-Pipeline by GlaxoSmithKline Plc, H2 2015 19

Germ Cell Tumors-Pipeline by MediGene AG, H2 2015 20

Germ Cell Tumors-Pipeline by Merck & Co., Inc., H2 2015 21

Germ Cell Tumors-Pipeline by Novartis AG, H2 2015 22

Germ Cell Tumors-Pipeline by Philogen S.p.A., H2 2015 23

Germ Cell Tumors-Pipeline by Sanofi, H2 2015 24

Assessment by Monotherapy Products, H2 2015 25

Assessment by Combination Products, H2 2015 26

Number of Products by Stage and Target, H2 2015 28

Number of Products by Stage and Mechanism of Action, H2 2015 30

Number of Products by Stage and Route of Administration, H2 2015 32

Number of Products by Stage and Molecule Type, H2 2015 34

Germ Cell Tumors Therapeutics-Recent Pipeline Updates, H2 2015 65

Germ Cell Tumors-Dormant Projects, H2 2015 86

List of Figures

Number of Products under Development for Germ Cell Tumors, H2 2015 8

Number of Products under Development for Germ Cell Tumors-Comparative Analysis, H2 2015 9

Number of Products under Development by Companies, H2 2015 10

Number of Products under Investigation by Universities/Institutes, H2 2015 11

Comparative Analysis by Clinical Stage Development, H2 2015 12

Comparative Analysis by Early Stage Products, H2 2015 13

Assessment by Monotherapy Products, H2 2015 25

Number of Products by Top 10 Targets, H2 2015 27

Number of Products by Stage and Top 10 Targets, H2 2015 27

Number of Products by Top 10 Mechanism of Actions, H2 2015 29

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015 29

Number of Products by Top 10 Routes of Administration, H2 2015 31

Number of Products by Stage and Top 10 Routes of Administration, H2 2015 31

Number of Products by Top 10 Molecule Types, H2 2015 33

Number of Products by Stage and Top 10 Molecule Types, H2 2015 33

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

AB Science SA

ArQule, Inc.

Astex Pharmaceuticals, Inc.

GlaxoSmithKline Plc

MediGene AG

Merck & Co., Inc.

Novartis AG

Philogen S.p.A.

Sanofi

Germ Cell Tumors Therapeutic Products under Development, Key Players in Germ Cell Tumors Therapeutics, Germ Cell Tumors Pipeline Overview, Germ Cell Tumors Pipeline, Germ Cell Tumors Pipeline Assessment


Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204

download

Company Brochure

Engage with Us

query [@] kenresearch.com